GS 9137

Known as: GS-9137, GS9137 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2012
02420062012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
In the present study, we report the exploration of binding modes of potent HIV-1 integrase (IN) inhibitors MK-0518 (raltegravir… (More)
Is this relevant?
2010
2010
The tautomerism and corresponding transition states of four authentic HIV-1 integrase (IN) inhibitor prototype structures, alpha… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
To gain further insight into the understanding of the antiviral resistance patterns and mechanisms of the integrase strand… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Two decades of intensive research efforts have led to the discovery of a large number of HIV-1 integrase (IN) inhibitors… (More)
Is this relevant?
Review
2008
Review
2008
The emergence of antiretroviral drug resistance in patients infected by the human immunodeficiency virus (HIV) has prompted… (More)
Is this relevant?
Review
2008
Review
2008
HIV-1 integrase (IN) catalyzes the integration of proviral DNA into the host genome, an essential step for viral replication… (More)
Is this relevant?
2007
2007
OBJECTIVES To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil… (More)
Is this relevant?
Review
2007
Review
2007
From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase. METHODS The antiviral activity… (More)
Is this relevant?
2006
2006
  • Reilly O'Neal
  • BETA : bulletin of experimental treatments for…
  • 2006
Possibly the most exciting news to come out of the 13th Conference on Retroviruses and Opportunistic Infections, held in Denver… (More)
Is this relevant?